Concluding Discussion: Pharmacoeconomic Factors Related to the Treatment of Schizophrenia

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Dr. H. Meltzer: Readers of this Supplement should find answers to questions such as: How should various stakeholders evaluate cost effectiveness? Is cost-utility analysis an accepted form of research? Why should managed care companies or government agencies be interested in pharmacoeconomic analysis?’ ‹